Supernus Pharmaceuticals (SUPN) is back in focus after reporting first quarter 2026 results that topped Wall Street earnings and revenue expectations, with Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO playing key roles.

Supernus Pharmaceuticals’ share price has been broadly steady in recent months, with a 2.7% 1 month share price decline and a roughly flat 90 day move. However, a 59.0% 1 year total shareholder return points to strong longer term momentum around the recent earnings beats and pipeline progress.

If strong Q1 results in CNS treatments have caught your attention, this can be a good moment to look across the sector and see what else is working in healthcare related AI, starting with 35 healthcare AI stocks

With the stock roughly flat over 3 months but up 59% over 1 year, and trading at a discount to the average analyst price target, the key question is whether there is still an opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 22.1% Undervalued

With Supernus Pharmaceuticals last closing at $49.19 versus a narrative fair value of $63.17, the current setup hinges on how its CNS portfolio and pipeline play out over time.

Expanding patient pool for core products, Qelbree and GOCOVRI, driven by increased prevalence and diagnosis of CNS disorders, as well as broader healthcare access (especially among Medicare patients, as seen with GOCOVRI’s prescription growth), is likely to sustain robust top-line revenue growth.

Read the complete narrative. Read the complete narrative.

Want to see what underpins that fair value gap? The widely followed narrative leans on rising CNS revenues, improving margins and a richer earnings profile over time. The crucial details sit in how those revenue paths, margin shifts and future profit multiples are stitched together. That is where the full narrative gets very specific.

Result: Fair Value of $63.17 (UNDERVALUED)

However, this depends on Qelbree and GOCOVRI continuing to account for a large share of sales, and on R&D projects like SPN-820 avoiding costly setbacks.

Next Steps

The setup appears to balance potential and concern. If this story interests you, take a closer look yourself and weigh both sides using 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Supernus has sharpened your interest in the sector, do not stop here. Widening your watchlist today could mean spotting tomorrow’s standouts before the crowd.

• Spot potential bargains early by scanning screener containing 25 high quality undiscovered gems that pair solid fundamentals with lower market attention.
• Prioritize staying power by reviewing the solid balance sheet and fundamentals stocks screener (46 results) to see which companies back their stories with stronger finances.
• Focus on protection and consistency by checking the 72 resilient stocks with low risk scores for stocks with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.